CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
-10.27%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.22B
AUM Growth
+$1.22B
(-18%)
Cap. Flow
-$1.35M
Cap. Flow
% of AUM
-0.11%
Top 10 Holdings %
Top 10 Hldgs %
79.8%
Holding
46
New
8
Increased
5
Reduced
10
Closed
2
Top Buys
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$10.9M |
| 2 |
MAZE
Maze Therapeutics, Inc. Common Stock
MAZE
|
$10.4M |
| 3 |
GE HealthCare
GEHC
|
$8.07M |
| 4 |
Hims & Hers Health
HIMS
|
$5.91M |
| 5 |
Standard BioTools
LAB
|
$5.21M |
Top Sells
| 1 |
Illumina
ILMN
|
$12.3M |
| 2 |
Sarepta Therapeutics
SRPT
|
$11M |
| 3 |
Exact Sciences
EXAS
|
$10.6M |
| 4 |
4D Molecular Therapeutics
FDMT
|
$6.41M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$5.4M |
Sector Composition
| 1 | Healthcare | 99.52% |
| 2 | Consumer Staples | 0.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
GeneDx Holdings
WGS
$3.72B
| $311M | 25.38% | 3,507,164 | – | – |
|
2
BioLife Solutions
BLFS
$1.2B
| $199M | 16.25% | 8,707,165 | – | – |
|
3
Revolution Medicines
RVMD
$7.1B
| $131M | 10.68% | 3,697,933 -1,350 | -0% | -$47.7K |
|
|
4
Standard BioTools
LAB
$481M
| $82.2M | 6.71% | 76,075,636 +4,820,959 | +7% | +$5.21M |
|
5
Avidity Biosciences
RNA
$5.99B
| $60.4M | 4.93% | 2,045,000 | – | – |
|
|
6
Sarepta Therapeutics
SRPT
$1.78B
| $57.5M | 4.7% | 900,783 -172,717 | -16% | -$11M |
|
|
7
Illumina
ILMN
$15.8B
| $47.2M | 3.86% | 595,000 -155,000 | -21% | -$12.3M |
|
|
8
Alnylam Pharmaceuticals
ALNY
$58.5B
| $32.4M | 2.65% | 120,000 -20,000 | -14% | -$5.4M |
|
|
BPMC
9
DELISTED
Blueprint Medicines
BPMC
| $28.9M | 2.36% | 326,378 | – | – |
|
10
Beam Therapeutics
BEAM
$1.66B
| $27.8M | 2.28% | 1,425,562 +175,562 | +14% | +$3.43M |
|
11
Relay Therapeutics
RLAY
$619M
| $23.8M | 1.95% | 9,098,574 +150,000 | +2% | +$393K |
|
12
Codexis
CDXS
$246M
| $21.8M | 1.78% | 8,100,000 | – | – |
|
|
VERV
13
DELISTED
Verve Therapeutics
VERV
| $18.3M | 1.49% | 3,995,571 | – | – |
|
|
14
Exact Sciences
EXAS
$8.98B
| $17.5M | 1.43% | 405,000 -245,000 | -38% | -$10.6M |
|
15
Neurogene
NGNE
$264M
| $15.2M | 1.24% | 1,295,361 | – | – |
|
16
Intellia Therapeutics
NTLA
$1.22B
| $14.2M | 1.16% | 2,000,000 | – | – |
|
17
Denali Therapeutics
DNLI
$2.23B
| $13.5M | 1.1% | 990,000 | – | – |
|
18
Structure Therapeutics
GPCR
$1.11B
| $12.1M | 0.99% | 700,000 | – | – |
|
|
ONC
19
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $10.9M | 0.89% | +40,000 | New | +$10.9M |
|
20
Guardant Health
GH
$8.41B
| $10.7M | 0.87% | 250,000 -100,000 | -29% | -$4.26M |
|
|
MAZE
21
Maze Therapeutics, Inc. Common Stock
MAZE
$635M
| $10.4M | 0.85% | +946,357 | New | +$10.4M |
|
|
TSVT
22
DELISTED
2seventy bio
TSVT
| $9.88M | 0.81% | 2,000,000 | – | – |
|
23
Veracyte
VCYT
$2.39B
| $8.19M | 0.67% | 276,308 | – | – |
|
|
24
GE HealthCare
GEHC
$33.7B
| $8.07M | 0.66% | +100,000 | New | +$8.07M |
|
25
Syndax Pharmaceuticals
SNDX
$1.41B
| $7.8M | 0.64% | 635,000 +160,000 | +34% | +$1.97M |
|